Author: Editor

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Céline Mascaux discusses treatment strategies in both the front line and relapse settings of EGFR+ tumors. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

With the recent news that Sen. John McCain was diagnosed with glioblastoma, Ashley Sumrall, MD, division chief of neuro-oncology at Levine Cancer Institute, explains the most common treatment options for those who have been afflicted by this particularly aggressive form of brain cancer.

Surgeon Anne Peled, MD and patient Sue Yeres — herself a breast cancer activist — tell the story of Sue’s healing after breast cancer, helped by the BioZorb implant. For more info, see http://www.focalrx.com.

Dr. David Edmonson describes how the BioZorb implant helps improve cosmetic results for breast cancer patients — while also aiding with the targeting of radiation treatment after surgery. Dr. Edmonson is a surgeon at Women & Infants Hospital, in Providence, R.I. More info: www.focalrx.com.

Trisha Marsolini, RN, OCN, BMTCN and Angela Rodriguez, MSN, RN, CNS-BC, AFN-BC, OCN, Associate Director of Clinical Operations Infusion/CTU/Phase 1 Clinical Trials of Seattle Cancer Care Alliance discuss Staffing Strategies for Best Practices in Oncology Infusions Ambulatory Clinics” To learn about joining our nursing team, click here: http://bit.ly/2sQAZKX

Kathleen Shannon Dorcy, PhD, RN, Director of Clinical Nursing Research of Seattle Cancer Care Alliance discusses Ethical Considerations of Precision Medicine for Oncology Nurses To learn about joining our nursing team, click here: http://bit.ly/2sQAVLd

Naomi Heinecke, LPN and Terri Cunningham, MSN, RN, AOCN of Seattle Cancer Care Alliance discuss Creating an Accurate Home Medication List in an Oncology Outpatient Clinic: Can it be Done? To learn about joining our nursing team, click here: http://bit.ly/2t4e5DO

Arlyce Coumar, BSN, RN, OCN, BMTCN of Seattle Cancer Care Alliance discusses A Model for Global Engagement of Oncology Nurses To learn about joining our nursing team, click here: http://bit.ly/2sQF7dS

Michelle Mitchell, BSN, RN, OCN, Sharon Rockwell, BSN, RN, OCN, CRNI, Alex Dorcy, BSN, RN, OCN, and Annette English, BSN, RN, OCN of Seattle Cancer Care Alliance discuss Advances in Immunotherapy and Patient-Centered Care in a Therapy-Specific Research Setting To learn about joining our nursing team, click here: http://bit.ly/2t4fgTN

Nicole Falkin, BSN, RN, OCN and Anne Nagengast, BSN, RN, BMTCN of Seattle Cancer Care Alliance discuss Managing Cytokine Release Syndrome in Immunotherapy Patients in an Ambulatory Clinic To learn about joining our nursing team, click here: http://bit.ly/2sQEVLv

Karen Anderson, MN, RN, AOCNS, BMTCN, CRNI and Anne Reese, BSN, RN, OCN of Seattle Cancer Care Alliance discuss Nursing Competencies in an Outpatient T-Cell Immunotherapy Clinical Trials Unit To learn more about joining our nursing team, click here: http://bit.ly/2sQobUH

Expanding beyond the checkpoints: New vaccines and other immunologic strategies for NSCLC Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

Unique toxicities of immunotherapy Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vassiliki Papadimitrakopoulou argues in favor of the use of combination therapy for targeting the immune system with checkpoint inhibitors. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Naiyer Rizvi argues in favor of single drug therapy for targeting the immune system with checkpoint inhibitors. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Andrew R. Haas discusses the biological basis of immunotherapy in the treatment of lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Joshua Bauml discusses whether there has been progress in the treatment of small cell lung cancer (SCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Evan W. Alley discusses the targeting of HER2, BRAF, KRAS, MET, and TRK mutations. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Ranee Mehra discusses the therapeutic implications of EML4/ALK, ROS-1 and other actionable biomarkers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Pallavi Kumar discusses strategies for how to conduct family meetings and end of life conversations. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this Velocity Vlog activity, Dr. Howard L. Kaufman of the Rutgers Cancer Institute, provides a brief overview of the incidence and epidemiology of Merkel cell carcinoma and then discusses clinical trial updates from the recent American Society of Clinical Oncology Annual Meeting in Chicago. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7263 © 2017 Imedex, LLC.

In this Ask the Expert segment, Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center responds to MPN community member, Susan. Susan asks if there are MPN treatments that reduce fibrosis or slow progression of the disease. Dr. Verstovsek explains the how the treatments work and discusses the possibility of reducing fibrosis and limiting disease progression. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

In this Ask the Expert segment, a Patient Power community member wants to know if and why a bone marrow biopsy is necessary if her essential thrombocythemia (ET) diagnosis is confirmed through blood work. Dr. Srdan Verstovsek responds by explaining what specific information is provided to the clinician by a bone marrow biopsy, specifically related to fibrosis, disease mutations, and how this information may affect prognosis and treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Jack West, MD of Swedish Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being incorporated into lung cancer treatment algorithms at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jack West, MD of Swedish Cancer Institute discusses the use of IDO inhibitors for the treatment of lung cancer patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jack West, MD of Swedish Cancer Institute discusses the use of durvalumab for patients with stage III non-small cell lung cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jack West, MD of Swedish Cancer Institute explains the relevance to test for PD-L1 in lung cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jack West, MD of Swedish Cancer Institute discusses the combination of immunotherapies for future clinical research at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jack West, MD of Swedish Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being combined with chemotherapy and targeted therapy for lung cancer treatment at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses the results of the LATITUDE study and its impact on clinical practice and future clinical research at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada explains how he chooses the right prostate cancer patient for Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada explains whether AR-V7 testing is ready for prime time at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses the data from the CHAARTED, STAMPEDE, and LATITUDE studies and their impact on treatment of prostate cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nicholas J. Vogelzang, MD of Comprehensive Cancer Centers of Nevada discusses cost implications when abiraterone becomes standard care for prostate cancer treatment. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debu Tripathy, MD of MD Anderson Cancer Center explains how immunotherapies are being studied and possibly integrated into the treatment of metastatic breast cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debu Tripathy, MD of MD Anderson Cancer Center gives an overview of the MONALEESA-2 study at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debu Tripathy, MD of MD Anderson Cancer Center gives an overview of the MONARCH-2 trial and explains its impact on treating and managing breast cancer patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debu Tripathy, MD of MD Anderson Cancer Center discusses the impact of the APHINITY trial on treating patients with breast cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Anurag Singh, MD, shares new research indicating that non-small cell lung cancer (NSCLC) patients may benefit from a single dose of stereotactic body radiation therapy (SBRT) as much as they would from three separate SBRT treatments. Read more: https://goo.gl/3I4mxf

Stereotactic body radiation therapy (SBRT) combined with surgery can be used to treat metastatic kidney cancer, according to Roswell Park researchers. The study is the first clinical trial to evaluate the immune effects of high-dose radiation therapy followed by surgery in patients with advanced kidney cancer, and may also set the stage for combination treatments incorporating immunotherapy. Learn more: https://goo.gl/RKj5Pf

George R. Simon, MD, FACP, FCCP of MD Anderson Cancer Center gives an overview of the Checkmate 032 and CTONG 1104 studies on non-small cell lung cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.         non-small cell lung cancer checkmate 032, checkmate 032, ctong 1104, checkmate 032 and ctong 1104 studies, 2017 annual meeting

George R. Simon, MD, FACP, FCCP of MD Anderson Cancer Center gives an overview of the most promising data on lung cancer presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

David S. Siegel, MD, PhD of John Theurer Cancer Center discusses the use of pomalidomide for multiple myeloma patients progressing on lenalidomide. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

David S. Siegel, MD, PhD of John Theurer Cancer Center discusses the use of CAR T-cell therapy in treating multiple myeloma at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

David S. Siegel, MD, PhD of John Theurer Cancer Center discusses the combination of pembrolizumab and lenalidomide for treating patients with multiple myeloma at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeff Sharman, MD of Willamette Valley Cancer Center discusses whether or not CAR T-cell therapy is promising for the treatment of non-hodgkin lymphoma. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeff Sharman, MD of Willamette Valley Cancer Center gives an overview of his presentation, which focused on the GENUINE trial for patients with chronic lymphocytic leukemia. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeff Sharman, MD of Willamette Valley Cancer Center discusses the emerging trends for management of chronic lymphocytic leukemia at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center discusses how and when he beings to speak with his patients about financial toxicity at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center gives an overview of the most intriguing and most promising clinical data on colorectal cancer presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.